MTUS1 and cancer: In conclusion, decreased MTUS1 expression in lung adenocarcinoma patients was significantly correlated with adverse clinicopathological factors and poor disease-free and cancer-specific survival, especially for patients at early stage and with surgical treatment only, suggesting that MTUS1 may be a potential biomarker for predicting clinical outcomes in lung adenocarcinoma patients.